Becton Dickinson beats quarterly estimates on strength in drug-delivery devices
Becton Dickinson surpassed analysts’ expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices.
Related Articles
Postpartum Depression Common After Cesarean Delivery
About 1 in 6 women were found to experience symptoms of postpartum depression 2 months after cesarean delivery.
Antibiotic-resistant bacteria could pose major health threat across Asia
A virulent new strain of antibiotic-resistant bacteria that causes severe disease could be spreading widely across Asia—posing significant challenges to global public health, a new…
More than just a number on a scale: The musculoskeletal impact of obesity
Obesity is more than just a number on a scale; it is a complex, chronic disease characterized by an excess of body fat that negatively…
In-Utero Sugar Restriction Cuts Offspring’s Risk for Diabetes, Hypertension
THURSDAY, Nov. 7, 2024 (HealthDay News) — Sugar restriction during the first 1,000 days after conception lowers a child’s risk for later developing type 2…
Why Publish in a British Society for Rheumatology journal?
The British Society for Rheumatology (BSR) is the leading UK specialist medical society for rheumatology and musculoskeletal care professionals. BSR owns t
FDA Suggests Removing Oral Phenylephrine as OTC Monograph Nasal Decongestant Ingredient
The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.
The Lāhainā Wildfires and ‘Āina Connectedness
This Viewpoint examines the disaster response and climate health concepts following the 2023 Lāhainā wildfires in Maui through the perspective of Native Hawaiian leaders and…
Grifols on track to meet 2024 targets despite third-quarter profit drop
Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the…
Canada approves GSK’s RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the…
Calls for peat products ban to be sped up
An MP has put forward a parliament bill for a ban on peat products to be accelerated.
